Omeros Corporation (OMER)

Market Cap	531.98M
Revenue (ttm)	n/a
Net Income (ttm)	-134.53M
Shares Out	57.95M
EPS (ttm)	-2.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	567,029
Open	9.86
Previous Close	9.61
Day's Range	9.18 - 10.03
52-Week Range	2.61 - 13.60
Beta	1.98
Analysts	Buy
Price Target	22.50 (+145.1%)
Earnings Date	Mar 31, 2025

About OMER

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunog...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 8, 2009
• Employees: 198
• Stock Exchange: NASDAQ
• Ticker Symbol: OMER
• Website: https://www.omeros.com

Analyst Forecast

According to 4 analysts, the average rating for OMER stock is "Buy." The 12-month stock price forecast is $22.5, which is an increase of 145.10% from the latest price.

Price Target

$22.5

(145.10% upside)

Analyst Consensus: Buy